Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.60
Bid: 2.50
Ask: 2.70
Change: -0.05 (-1.89%)
Spread: 0.20 (8.00%)
Open: 2.65
High: 2.65
Low: 2.60
Prev. Close: 2.65
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

Tue, 19th Mar 2024 19:47

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

TMT Investments PLC - venture capital investor in high-growth technology companies - Reports net asset value per share of USD6.62 in the year ending December 31, rising 3.3% from USD6.41 the year prior. Total NAV rose to USD208.1 million from USD201.7 million. Explains improvement was mainly as a result of the upward revaluation of Backblaze and Collectly during the period. "With no financial debt and cash and cash equivalent reserves of USD11.0 million," TMT is "well positioned to ride out the current market volatility and to continue making investments and realising full and partial disposals when the right opportunities present themselves."

----------

Ten Lifestyle Group PLC - London-based lifestyle and travel services company - Issues trading update for six months to February 29. Expects to report half year net revenue of around GBP30.9 million, unchanged from last year, or up 4% at constant currency. Says active members continue to grow, up 13% to 356,000 from 316,000 last year. Explains the group secured and launched some significant contracts during the period that are expected to generate revenue in the second half of the year. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be around GBP5.3 million, up from GBP5.0 million last year. At the end of the first half, says cash and cash equivalents were GBP8.0 million, compared to GBP8.2 million at the previous year-end.

----------

First Class Metals PLC - Ontario, Canada-focused exploration company - Signs sixty day exclusivity agreement with Emerald Geological Services Ltd in respect of an earn-in to the McInnes Lake Property in Ontario. Chief Executive Marc Sale comments: "This is an exciting development for FCM greenfield exploration opportunities on a property which potentially contains the same structure that is present at Red Lake. The lack of previous systematic or comprehensive exploration in a favourable geological setting presents realistic expectation for a significant discovery." Pays CAD5,000, around GBP2,897, for the exclusivity period.

----------

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Starts search for a chief executive officer to lead the next stage of growth. Expects the process may take a number of months, during which period Suzy Dilly will remain as CEO. As part of the re-structuring process, Dilly and the board will consider potential alternative roles. In addition, Adrian de Courcey joins the board as non-executive director.

----------

Atlantic Lithium Ltd - lithium development company, currently focused on developing the Ewoyaa project on the Ghanaian coast - Announces further broad and high-grade assay results from resource drilling completed at the Ewoyaa lithium project in Ghana. Notes multiple high-grade and broad extensional drill intersections reported at the new Dog-Leg target. Describes results at Dog-Leg as "significant". Points out drilling has intersected shallow dipping, near surface mineralised pegmatite bodies with true thicknesses up to 35m outside of the mineral resource estimate, proving potential for significant resource growth. Plans to advance the drilling programme to be undertaken in 2024. A mineral resource estimate upgrade, for both lithium and feldspar, to incorporate all 2023 and 2024 drilling, is targeted for the second half of 2024.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Agrees to buy Chronos Therapeutics Ltd for initial GBP899,481, or 1.44 pence per share. Explains price could rise to GBP3.4 million subject to the achievement of certain milestones. Chronos features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage. Further, raises GBP0.85 million via placing and subscription at 1p each. In addition, announces retail offer to raise up to GBP1 million. Proceeds of the fund raise will be used for working capital and to maintain the enlarged group's patent portfolio. Plans name change to TheraCryf PLC.

----------

Impellam Group PLC - Luton, England-based specialist recruitment solutions provider - Says High Court sanctions scheme by which bid from HeadFirst Global BV will be facilitated. Expects scheme to become effective on Thursday, when shares will also be suspended.

----------

Custodian Property Income Reit PLC - real estate investment trust - Shareholders back resolution allowing company to allot shares or grant rights to subscribe for or convert any security into shares in the company in connection with the recommended merger with abrdn Property Income Trust Ltd. Chair David MacLellan says: "The board is pleased with the outcome of the vote, which demonstrated a very strong support from the CREI shareholders and further derisks the execution of the recommended merger." Encourages API shareholders to vote in favour of the scheme.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 Jun 2014 10:00

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Read more
10 Jun 2014 09:45

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

Read more
15 May 2014 13:31

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

Read more
1 May 2014 10:15

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

Read more
8 Apr 2014 11:05

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6

Read more
1 Apr 2014 09:22

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

Read more
19 Mar 2014 12:10

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

Read more
20 Feb 2014 11:10

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

Read more
31 Jan 2014 13:03

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

Read more
27 Dec 2013 08:27

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
15 Nov 2013 12:39

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 12:37

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Read more
15 Nov 2013 10:28

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.